1-(4-异丙基)苄基-5-氧代吡咯啉-3-甲酸 | 63674-51-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-(4-异丙基)苄基-5-氧代吡咯啉-3-甲酸
• 中文别名: 1-(4-异丙基苯基)-5-氧代吡咯啉-3-甲酸
• 英文名称: 1-(4-isopropyl-phenyl)-5-oxo-pyrrolidine-3-carboxylic acid
• 英文别名: 1-(4-Isopropylphenyl)-5-oxo-3-pyrrolidinecarboxylic acid；1-(4-Isopropylphenyl)-5-oxopyrrolidine-3-carboxylic acid；5-oxo-1-(4-propan-2-ylphenyl)pyrrolidine-3-carboxylic acid
• CAS: 63674-51-1
• 化学式: C₁₄H₁₇NO₃
• mdl: MFCD02197521
• 分子量: 247.294
• InChiKey: DIVQVOIDVFIFAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  1-(4-异丙基)苄基-5-氧代吡咯啉-3-甲酸 在 甲醇 、 sodium tetrahydroborate 、 硫酸 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 methanesulfonic acid 1-(4-isopropyl-phenyl)-5-oxo-pyrrolidin-3-ylmethyl ester
  参考文献：
  名称：

  Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosyntheses

  摘要：

  The synthesis of a series of 4[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their evaluation for inhibitory capacity toward fatty-acid and sterol biosyntheses using rats' liver slices in vitro and rabbits in vivo, are described. Among the compounds synthesized, 7e, 7g, 7h, 7i, 7k, 7r, 21, 23 and 29a b showed a potent inhibitory activity toward fatty-acid and sterol biosyntheses. Their IC(50)s were 4.4-6.8 x 10(-6) M and 6.6-9.8 x 10(-6) M, respectively. These activities were always superior to those of compounds I, II, III and Clinofibrate as references. The inhibitory activity toward the sterol biosynthesis of these compounds was inferior to that of Pravastatin. The reducing effects of the representative compounds (7e and 7l) toward plasma cholesterols and triglyceride were evaluated in Japanese white rabbits (30 and 100 mg/kg, po) and compared with those of Clinofibrate:and Pravastatin; The compounds showed a similar hypocholesterolemic effect to Pravastatin and a more potent hypotriglycemic effect than Clinofibrate and Pravastatin in this animal model. Thus, a dual,action of hypolipidemic effects was noted in 7e and 7l compared with the references.

  DOI：

  10.1016/0223-5234(94)90029-9
• 作为产物：
  描述：

  衣康酸 、 4-异丙基苯胺 在 乙酸乙酯 作用下， 以 sodium hydroxide 为溶剂， 反应 2.83h， 以to obtain 1-(4-isopropyl-phenyl)-5-oxo-pyrrolidine-3-carboxylic acid (1.0 g, 75%)的产率得到1-(4-异丙基)苄基-5-氧代吡咯啉-3-甲酸
  参考文献：
  名称：

  Heterocyclic compounds as adenosine receptor antagonist

  摘要：

  本公开的化合物是式（I）的融合嘧啶化合物，其互变异构体、多晶型、立体异构体、前药、溶剂化物或其药学上可接受的盐，作为腺苷受体拮抗剂。公开还描述了它们的制备过程。

  公开号：

  US08252797B2

文献信息

• HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST
  申请人：Palle Venkata

  公开号：US20090298744A1

  公开（公告）日：2009-12-03

  Compounds of the present disclosure are fused pyrimidine compounds of formula (I), its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, as Adenosine receptor antagonists. Processes of their preparation are also described in the disclosure.

  本公开的化合物是公式（I）的融合嘧啶化合物，其互变异构体，多晶形态，立体异构体，前药，溶剂合物或其药学上可接受的盐，作为腺苷受体拮抗剂。本公开还描述了它们的制备过程。
• AMINOPYRIMIDINES AS SYK INHIBITORS
  申请人：Altman Michael D.

  公开号：US20120277192A1

  公开（公告）日：2012-11-01

  The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

  本发明提供了一种新型的嘧啶胺化合物(I)，它是脾酪氨酸激酶的有效抑制剂，可用于治疗和预防由该酶介导的疾病，如哮喘、COPD和类风湿性关节炎。
• Heterocyclic compounds as adenosine receptor antagonist
  申请人：Advinus Therapeutics Pvt. Ltd.

  公开号：US08252797B2

  公开（公告）日：2012-08-28

  Compounds of the present disclosure are fused pyrimidine compounds of formula (I), its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, as Adenosine receptor antagonists. Processes of their preparation are also described in the disclosure.

  本公开的化合物是式（I）的融合嘧啶化合物，其互变异构体、多晶型、立体异构体、前药、溶剂化物或其药学上可接受的盐，作为腺苷受体拮抗剂。公开还描述了它们的制备过程。
• Aminopyrimidines as SYK Inhibitors
  申请人：Altman Michael D.

  公开号：US20140243290A1

  公开（公告）日：2014-08-28

  The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

  本发明提供了一种新的嘧啶胺化合物(I)，其是脾酪氨酸激酶的有效抑制剂，并且可用于治疗和预防由该酶介导的疾病，如哮喘、慢性阻塞性肺病和类风湿性关节炎。
• Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS
  申请人：TAIHO PHARMACEUTICAL COMPANY, LIMITED

  公开号：EP1000620A1

  公开（公告）日：2000-05-17

  Lp(a)-lowering agents or apo(a) production inhibitors containing as the active ingredient phenylcarboxylic acid derivatives represented by general formula (1) or salts thereof, wherein R1 represents optionally substituted phenyl; A represents lower alkylene or lower alkyleneoxy; B represents methylene or carbonyl; D represents lower alkylene; E represents lower alkylene or lower alkenylene; R2 represents hydrogen or lower alkyl; and l, m and n are each 0 or 1. These drugs can significantly lower Lp(a) while scarcely showing any side effects.

  Lp(a)降低剂或apo(a)生成抑制剂，其活性成分为通式(1)代表的苯基羧酸衍生物或其盐类，其中R1代表任选取代的苯基；A代表低级亚烷基或低级亚烷氧基；B代表亚甲基或羰基；D代表低级亚烷基；E代表低级亚烷基或低级亚烯基；R2代表氢或低级亚烷基；l、m和n均为0或1。这些药物可以大大降低脂蛋白（a），同时几乎没有任何副作用。